[Ovarian cancer--therapeutic options after the failure of the first line of treatment].
Ovarian cancer is the fifth leading cause of cancer deaths in women. The "gold standard" of the first line setting is taxanes and platinum-based chemotherapy. Despite substantial response, most women with ovarian cancer are destined to relapse, which occurs in 18-22 months. Management of recurrent ovarian cancer is still challenging. In this article we reviewed recent methods of treatment of the relapsed ovarian cancer: chemotherapy, radiotherapy and experimental approaches. Platines-derivates monotherapy seems to be the most adequate treatment for the platinum-sensitive ovarian cancer (carboplatin). Patients with platinum-refractory ovarian cancer should be considered for oral etoposide, radiotherapy or topotecan according to the current course of the disease. Once ovarian cancer recurs, cure is no longer a realistic goal. So it is important to realize, that the benefit with improved quality of life and relieving symptoms will be the main aspect of this treatment.